News | July 05, 2023
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
